- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06387186
Leucine Enriched Essential Amino Acid Powder as an Add-on to a Classic Ketogenic Diet in Refractory Epilepsy
April 23, 2024 updated by: Elizabeth Anne Thiele
Open Label, Single-Arm Study of the Safety and Tolerability of a Leucine Enriched Essential Amino Acid Powder as an Add-on to a Classic Ketogenic Diet in Refractory Epilepsy
The main purpose of this study is to evaluate the safety and tolerability of a Leucine-Enriched Essential Amino Acid (LEAA) Powder as an add-on to a classic ketogenic diet (KD) in pediatric and adult patients with refractory epilepsy.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a single center, single-arm, open label study to evaluate the safety, tolerability, and nutritional effect of Leucine-Enriched Essential Amino Acid powder (LEAA) when added to classical KD in pediatric and adult patients whose epilepsy is insufficiently controlled on the diet.
The study will enroll patients who have previously been compliant with their classical KD regimen for at least 28 days prior to enrollment and have experienced some response (≥40% reduction in seizures), but not complete response (<90% reduction in seizures) to dietary management with KD.
Study duration is 84 days and will have 3 remote study visits (Baseline- Remote Visit 1, Dose Adjustment- Remote Visit 2, and Final- Remote Visit 3) and a pre-screening communication via telephone/video.
Study Type
Interventional
Enrollment (Estimated)
15
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Carolyn Wilson
- Email: cwilson41@mgh.harvard.edu
Study Contact Backup
- Name: Lydia Tsega, MD, MPH
- Phone Number: 6177266524
- Email: ltsega@mgh.harvard.edu
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
Contact:
- Carolyn Wilson
- Email: cwilson41@mgh.harvard.edu
-
Contact:
- Lydia Tsega, MD, MPH
- Phone Number: 617-726-6524
- Email: ltsega@mgh.harvard.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male or female patients ages 2 years and up at enrollment.
- A diagnosis of epilepsy, with at least 2 seizures per week according to the parent/guardian report to study staff and investigator medical notes if applicable. All seizure types allowed.
- Under stable treatment with a classic ketogenic diet (KD) regimen with a KD ratio ≥ 1:1, with or without antiseizure medications (ASMs), for at least 28 days with documented, partial response (≥40% reduction in seizures), but not a complete response (<90% reduction in seizures) based on patient medical records or parental report.
- Patient and/or parent/caregiver able and willing to follow all study procedures and successfully complete the study.
Exclusion Criteria:
- Patients who have changed their KD regimen or antiseizure medication (ASM) or vagus nerve stimulation (VNS) within the last 28 days.
- Allergy, sensitivity to, or inability to metabolize any component of leucine enriched essential amino acid (LEAA).
- Those who are pregnant or breastfeeding.
- Patients who have received an investigational drug or product or participated in a drug study within 4 weeks before the first dose of leucine enriched essential amino acid (LEAA) powder.
- Patients who have a clinically significant condition or have had either clinically relevant symptoms or a clinically significant illness in the 4 weeks prior to the Baseline Visit 1, other than epilepsy, that would negatively impact study participation, collection of study data, or pose a risk to the patient including liver disease.
- Patients with history of suicidal ideation in past 6-months and suicidal behavior in past 2-years
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Leucine-Enriched Essential Amino Acid powder (LEAA)
Leucine-Enriched Essential Amino Acid powder (LEAA) as an add-on to a classic ketogenic diet (KD)
|
Leucine-Enriched Essential Amino Acid Powder will be orally/enterally administered by mixing in water or ketogenic formula.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with treatment-related adverse events
Time Frame: Baseline, 3 weeks, 12 weeks
|
Number of participants with treatment-related adverse events as reported by the trial participants.
|
Baseline, 3 weeks, 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with improved nutritional status as assessed by weight.
Time Frame: Baseline, 3 weeks, 12 weeks
|
Nutritional status will be assessed by measuring participants' weight in kilograms.
|
Baseline, 3 weeks, 12 weeks
|
Number of participants with improved nutritional status as assessed by body mass index (BMI).
Time Frame: Baseline, 3 weeks, 12 weeks
|
Nutritional status will be assessed by measuring participants' weight in kilograms and height in meters to assess their body mass index (BMI).
|
Baseline, 3 weeks, 12 weeks
|
Number of participants with improved nutritional status as assessed by serum ketone and glucose level.
Time Frame: At each visit and on next day
|
Serum ketone and glucose level will be measure before and after intake of investigational medicine.
|
At each visit and on next day
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in seizure frequency as assessed by seizure diary.
Time Frame: Baseline, 3 weeks, 12 weeks
|
Daily record of seizure type, duration, and frequency on seizure diary will be used to measure seizure changes.
|
Baseline, 3 weeks, 12 weeks
|
Changes in behavior and cognitive function as assessed by a questionnaire.
Time Frame: Baseline, 3 weeks, 12 weeks
|
Global assessment on behavior and cognitive function questionnaire will be used by study subject/parent/caregiver to assess behavior and cognitive function.
|
Baseline, 3 weeks, 12 weeks
|
Changes in seizure severity and overall health as assessed by a questionnaire.
Time Frame: Baseline, 3 weeks, 12 weeks
|
Global assessment on seizure severity, and overall health questionnaire will be used by clinician/dietitian and study subject/parent/caregiver to assess changes in seizure severity and overall health.
|
Baseline, 3 weeks, 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Elizabeth Thiele, MD, PhD, Massachusetts General Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
April 1, 2024
Primary Completion (Estimated)
March 31, 2025
Study Completion (Estimated)
March 31, 2025
Study Registration Dates
First Submitted
April 16, 2024
First Submitted That Met QC Criteria
April 23, 2024
First Posted (Actual)
April 26, 2024
Study Record Updates
Last Update Posted (Actual)
April 26, 2024
Last Update Submitted That Met QC Criteria
April 23, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023P003233
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Drug Resistant Epilepsy
-
NaviFUS CorporationTaipei Veterans General Hospital, TaiwanCompletedDrug Resistant Epilepsy | Epilepsy, Drug Resistant | Intractable Epilepsy | Refractory Epilepsy | Drug Refractory Epilepsy | Epilepsy, Drug Refractory | Epilepsy, Intractable | Medication Resistant EpilepsyTaiwan
-
Mansoura University HospitalUnknown
-
Nova Scotia Health AuthorityNot yet recruitingEpilepsy, Drug ResistantCanada
-
The Hospital for Sick ChildrenSt. Justine's HospitalCompletedEpilepsy, Drug ResistantCanada
-
Icahn School of Medicine at Mount SinaiNational Institute of Mental Health (NIMH)Recruiting
-
Instituto Mexicano del Seguro SocialCompletedEpilepsy, Drug ResistantMexico
-
MGC Pharmaceuticals d.o.oNot yet recruitingResistant Epilepsy, Drug | Adolescent Epilepsy | Children Epilepsy | Children and Adolescents With Resistant EpilepsiesIsrael, Slovenia
-
Centre Hospitalier St AnneFondation de l'Avenir; Fondation pour les Sciences du Cerveau; Association NEUROREFSTerminatedPartial Drug-resistant EpilepsyFrance
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, France; ICM Co....Recruiting
-
University of Medicine and Pharmacy at Ho Chi Minh...RecruitingEpilepsy, Drug Resistant | Acupuncture TherapyVietnam
Clinical Trials on Leucine-Enriched Essential Amino Acid powder
-
The Cleveland ClinicRecruitingCirrhosis, LiverUnited States
-
University of NottinghamAjinomoto Co., Inc.Unknown
-
Texas A&M UniversityRecruiting
-
Texas A&M UniversityUnknownChronic Obstructive Pulmonary DiseaseUnited States
-
McMaster UniversityCanadian Institutes of Health Research (CIHR); University of California, Davis and other collaboratorsCompletedRegulation of Muscle Protein SynthesisCanada
-
Texas A&M UniversityArkansas Children's Hospital Research InstituteCompletedCystic FibrosisUnited States
-
University Hospital, ToulouseTerminated
-
University of TorontoAjinomoto Co., Inc.CompletedHealthy | Increased Metabolic Requirement
-
Daniel MooreRecruitingInterventionalCanada
-
United States Army Research Institute of Environmental...US Army Natick Soldier Research, Development & Engineering CenterCompletedMuscle Loss | Muscle Anabolism | Muscle PerformanceUnited States